Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Nogapendekin alfa inbakicept |
Trade Name | Anktiva |
Synonyms | N-803|N803|N 803|nogapendekin alfa|ALT803|ALT 803|ALT-803 |
Drug Descriptions |
Anktiva (nogapendekin alfa inbakicept) is a fusion protein comprising a mutant version of IL-15 with increased activity and IL-15Ra fused to the Fc region of IgG1, which activates CD8+ T-cells and promotes effector activity, potentially resulting in increased antitumor immune response (PMID: 24404427, PMID: 31338557). Anktiva (nogapendekin alfa inbakicept) in combination with BCG is FDA approved for use in patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors (FDA.gov). |
DrugClasses | |
CAS Registry Number | 1850381-92-8 |
NCIT ID | C107503 |